Evidence map›Paper›PMID 39354196›Full record

Trial reportNature medicine2024

Sacituzumab govitecan in HR

Binghe Xu, Shusen Wang, Min Yan, Joohyuk Sohn, Wei Li, Jinhai Tang, Xiaojia Wang, Ying Wang, Seock-Ah Im, Dongdong Jiang and 8 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Binghe XuCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xubinghe@medmail.com.cn.ORCID http://orcid.org/0000-0003-4195-337X
Shusen WangSun Yat-sen University Cancer Center, Guangzhou, China.ORCID http://orcid.org/0000-0003-0139-5780
Min YanHenan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.ORCID http://orcid.org/0000-0002-3911-748X
Joohyuk SohnYonsei Cancer Center, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-2303-2764
Wei LiThe First Hospital of Jilin University, Changchun, China.
Jinhai TangThe First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaojia WangZhejiang Cancer Hospital, Hangzhou, China.ORCID http://orcid.org/0000-0002-7005-0842
Ying WangSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Seock-Ah ImSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.
Dongdong JiangGilead Sciences Inc., Shanghai, China.
Theresa ValdezGilead Sciences Inc., Foster City, CA, USA.
Anandaroop DasguptaGilead Sciences Inc., Foster City, CA, USA.
Yiran ZhangGilead Sciences Inc., Foster City, CA, USA.
Yilin YanGilead Sciences Inc., Foster City, CA, USA.
Kimberly M KomatsubaraGilead Sciences Inc., Foster City, CA, USA.
Wei-Pang ChungNational Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID http://orcid.org/0000-0001-8485-270X
Fei MaCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0001-9432-1902
Ming-Shen DaiTri-Service General Hospital, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsCamptothecinErb-b2 Receptor Tyrosine KinasesAdultAgedFemaleHumansImmunoconjugatesMiddle AgedNeoplasm MetastasisProgression-Free SurvivalReceptors, EstrogenReceptors, ProgesteroneAntibodies, Monoclonal, HumanizedCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesReceptors, EstrogenReceptors, Progesteronesacituzumab govitecan

Identifiers

PMID39354196
PMCPMC11645259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.